Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 1

Гиперурикемия и артериальная гипертония: взаимосвязи и риски
Н.В. Блинова, И.Е. Чазова

Список литературы

1. Stevens G, Mascarenhas M, Mathersa C. Global health risks: progress and challenges. Bulletin of World Health Orgaization 2009 Sep;87(9):646.
2. Mahomed FA. On chronic Bright’s disease, and its essential symptoms. The Lancet 1879 Mar;1:389-404.
3. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart (British Cardiac Society) 2013 Jun;99(11):759-66.
4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. The American Journal of Medicine 2012 Jul;125(7):679-87.e1.
5. Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ, Murthy BVR, Hegarty A, Hannigan A, Nguyen HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013 Jul;106(7):647-58.
6. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care & Research (Hoboken) 2011 Jan;63(1):102-10.
7. Liu L, Gu Y, Li C, Zhang Q, Meng G, Wu H, Du H, Shi H, Xia Y, Guo X, Liu X, Bao X, Su Q, Fang L, Yu F, Yang H, Yu B, Sun S, Wang X, Zhou M, Jia Q, Guo Q, Song K, Huang G, Wang G, Niu K. Serum uric acid is an independent predictor for developing prehypertension: a population-based prospective cohort study. Journal of Human Hypertension 2017 Feb;31(2):116-20.
8. Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, Nakagawa T, Andres-Hernando A, Sato Y, Jensen T, Garcia G, Rodriguez-Iturbe B, Ohno M, Lanaspa MA, Johnson RJ. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension (Dallas, Tex.: 1979) 2018 Jan;71(1):78-86.
9. Tatsumi Y, Asayama K, Morimoto A, Satoh M, Sonoda N, Miyamatsu N, Ohno Y, Miyamoto Y, Izawa S, Ohkubo T. Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study. Hypertension Research 2020 May;43(5):442-9.
10. Cheng YB, Li Y. Hyperuricemia: does it matter for the progression from prehypertension to hypertension? Hypertension (Dallas, Tex.: 1979) 2018 Jan;71(1):66-7.
11. Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R, Weiss G, Stofferin H, Jaschke W. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiology 2019 Oct;4(10):1019-28.
12. Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension (Dallas, Tex.: 1979) 2018 Sep;72(3):582-4.
13. Huang Z, Hong Q, Zhang X, Xiao W, Wang L, Cui S, Feng Z, Lv Y, Cai G, Chen X, Wu D. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Communication and Signaling 2017 Jan;15(1):3.
14. Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, Cicerchi C, Li N, Kuwabara M, Roncal-Jimenez CA, Johnson RJ, Lanaspa MA. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. The Journal of Biological Chemistry 2019 Mar;294(11):4272-81.
15. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe BR, Nakagawa T, Kang DH, Sautin YY, Johnson RJ. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. The Journal of Biological Chemistry 2012 Nov;287(48):40732-44.
16. Wilson C, Lee MD, Heathcote HR, Zhang X, Buckley C, Girkin JM, Saunter CD, McCarron JG. Mitochondrial ATP production provides long-range control of endothelial inositol trisphosphate-evoked calcium signaling. The Journal of Biological Chemistry 2019 Jan;294(3):737-58.
17. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. The New England Journal of Medicine 1966 Sep;275(9):457-64.
18. Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine 2017 Jan;37:38-42.
19. Giallauria F, Predotti P, Casciello A, Grieco A, Russo A, Viggiano A, Citro R, Ravera A, Ciardo M, Guglielmi M, Maggio M, Vigorito C. Serum uric acid is associated with non-dipping circadian pattern in young patients (30–40 years old) with newly diagnosed essential hypertension. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2016;38(2):233-7.
20. Lepeytre F, Lavoie PL, Troyanov S, Madore F, Agharazii M, Goupil R. Uric acid association with pulsatile and steady components of central and peripheral blood pressures. Journal of Hypertension 2018 Mar;36(3):495-501.
21. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, Kato E. Serum uric acid and the renin-angiotensin system in hypertension. Journal of the American Geriatrics Society 1978 Jun;26(6):241-7.
22. Qin T, Zhou X, Wang J, Wu X, Li Y, Wang L, Huang H, Li J. Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta-analysis. Journal of Clinical Hypertension (Greenwich, Conn.) 2016 Dec;18(12):1268-78.
23. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16(1):6-31.
24. Kahn AM. Effect of diuretics on the renal handling of urate. Seminars in Nephrology 1988 Sep;8(3):305-14.
25. Choi HK, Soriano LC, Zhang Y, García Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012 Jan;344:d8190.
26. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annual Review of Physiology 2015;77:323-45.
27. Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990 Apr;300(7630):975-8.
28. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., Недогода С.В., Подзолков В.И., Ощепкова Е.В., Медведева И.В., Миронова О.Ю., Блинова Н.В. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии 2019;16(4):8-21.
29. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Current Opinion in Rheumatology 2011 Mar;23(2):192-202.
30. Schlesinger N. Dietary factors and hyperuricaemia. Current Pharmaceutical Design 2005;11(32):4133-8.
31. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, Fukuhara M, Uezono K, Morinaga Y, Ohta Y, Otonari T, Kawasaki J, Kato I, Tsuchihashi T; COMFORT Investigators. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2015;37(3):192-6.
32. Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2018 Feb;20(2):458-62.
33. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. The New England Journal of Medicine 2018 Mar;378(13):1200-10.
34. Mitnala S, Phipps-Green A, Franklin C, Horne A, Stamp LK, Merriman TR, Dalbeth N. Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology (Oxford, England) 2016 Jul;55(7):1172-6.
35. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. The American Journal of Medicine 1984 Jan;76(1):47-56.
36. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases 2017 Sep;76(9):1522-8.
37. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008 Aug;300(8):924-32.
38. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension (Dallas, Tex.: 1979) 2012 Nov;60(5):1148-56.
39. Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart (British Cardiac Society) 2014 Jul;100(14):1085-92.
40. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clinical Endocrinology (Oxford, England) 2015 Oct;83(4):475-82.
41. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2014 Nov;64(5):1102-7.
42. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of Medicine 2017 Mar;49(2):142-56.
43. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Archives of Internal Medicine 2010 Aug;170(15):1358-64.
44. MacIsaac RL, Salatzki J, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2016;67(3):535-40.
45. Инструкция по медицинскому применению лекарственного препарата Милурит®, регистрационное удостоверение П N012684/01 от 06.11.19.

References

1. Stevens G, Mascarenhas M, Mathersa C. Global health risks: progress and challenges. Bulletin of World Health Organization 2009 Sep;87(9):646.
2. Mahomed FA. On chronic Bright’s disease, and its essential symptoms. The Lancet 1879;1:389-404.
3. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart (British Cardiac Society) 2013 Jun;99(11):759-66.
4. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. The American Journal of Medicine 2012 Jul;125(7):679-87.e1.
5. Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ, Murthy BVR, Hegarty A, Hannigan A, Nguyen HT. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 2013 Jul;106(7):647-58.
6. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care & Research (Hoboken) 2011 Jan;63(1):102-10.
7. Liu L, Gu Y, Li C, Zhang Q, Meng G, Wu H, Du H, Shi H, Xia Y, Guo X, Liu X, Bao X, Su Q, Fang L, Yu F, Yang H, Yu B, Sun S, Wang X, Zhou M, Jia Q, Guo Q, Song K, Huang G, Wang G, Niu K. Serum uric acid is an independent predictor for developing prehypertension: a population-based prospective cohort study. Journal of Human Hypertension 2017 Feb;31(2):116-20.
8. Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, Nakagawa T, Andres-Hernando A, Sato Y, Jensen T, Garcia G, Rodriguez-Iturbe B, Ohno M, Lanaspa MA, Johnson RJ. Uric acid is a strong risk marker for developing hypertension from prehypertension: a 5-year Japanese cohort study. Hypertension (Dallas, Tex.: 1979) 2018 Jan;71(1):78-86.
9. Tatsumi Y, Asayama K, Morimoto A, Satoh M, Sonoda N, Miyamatsu N, Ohno Y, Miyamoto Y, Izawa S, Ohkubo T. Hyperuricemia predicts the risk for developing hypertension independent of alcohol drinking status in men and women: the Saku study. Hypertension Research 2020 May;43(5):442-9.
10. Cheng YB, Li Y. Hyperuricemia: does it matter for the progression from prehypertension to hypertension? Hypertension (Dallas, Tex.: 1979) 2018 Jan;71(1):66-7.
11. Klauser AS, Halpern EJ, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R, Weiss G, Stofferin H, Jaschke W. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiology 2019 Oct;4(10):1019-28.
12. Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension (Dallas, Tex.: 1979) 2018 Sep;72(3):582-4.
13. Huang Z, Hong Q, Zhang X, Xiao W, Wang L, Cui S, Feng Z, Lv Y, Cai G, Chen X, Wu D. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Communication and Signaling 2017 Jan;15(1):3.
14. Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, Cicerchi C, Li N, Kuwabara M, Roncal-Jimenez CA, Johnson RJ, Lanaspa MA. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. The Journal of Biological Chemistry 2019 Mar;294(11):4272-81.
15. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iturbe BR, Nakagawa T, Kang DH, Sautin YY, Johnson RJ. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. The Journal of Biological Chemistry 2012 Nov;287(48):40732-44.
16. Wilson C, Lee MD, Heathcote HR, Zhang X, Buckley C, Girkin JM, Saunter CD, McCarron JG. Mitochondrial ATP production provides long-range control of endothelial inositol trisphosphate-evoked calcium signaling. The Journal of Biological Chemistry 2019 Jan;294(3):737-58.
17. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. The New England Journal of Medicine 1966 Sep;275(9):457-64.
18. Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine 2017 Jan;37:38-42.
19. Giallauria F, Predotti P, Casciello A, Grieco A, Russo A, Viggiano A, Citro R, Ravera A, Ciardo M, Guglielmi M, Maggio M, Vigorito C. Serum uric acid is associated with non-dipping circadian pattern in young patients (30–40 years old) with newly diagnosed essential hypertension. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2016;38(2):233-7.
20. Lepeytre F, Lavoie PL, Troyanov S, Madore F, Agharazii M, Goupil R. Uric acid association with pulsatile and steady components of central and peripheral blood pressures. Journal of Hypertension 2018 Mar;36(3):495-501.
21. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, Kato E. Serum uric acid and the renin-angiotensin system in hypertension. Journal of the American Geriatrics Society 1978 Jun;26(6):241-7.
22. Qin T, Zhou X, Wang J, Wu X, Li Y, Wang L, Huang H, Li J. Hyperuricemia and the prognosis of hypertensive patients: a systematic review and meta-analysis. Journal of Clinical Hypertension (Greenwich, Conn.) 2016 Dec;18(12):1268-78.
23. Chazova IE, Zhernakova YuV on behalf of experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension 2019;16(1):6-31 (In Russian).
24. Kahn AM. Effect of diuretics on the renal handling of urate. Seminars in Nephrology 1988 Sep;8(3):305-14.
25. Choi HK, Soriano LC, Zhang Y, García Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012 Jan;344:d8190.
26. Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. Annual Review of Physiology 2015;77:323-45.
27. Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990 Apr;300(7630):975-8.
28. Chazova IE, Zhernakova YuV, Kislyak OA, Nedogoda SV, Podzolkov VI, Oshchepkova EV, Medvedeva IV, Mironova OYu, Blinova NV. Consensus on management of patients with hyperuricemia and high cardiovascular risk. Systemic Hypertension 2019;16(4):8-21 (In Russian).
29. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Current Opinion in Rheumatology 2011 Mar;23(2):192-202.
30. Schlesinger N. Dietary factors and hyperuricaemia. Current Pharmaceutical Design 2005;11(32):4133-8.
31. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, Fukuhara M, Uezono K, Morinaga Y, Ohta Y, Otonari T, Kawasaki J, Kato I, Tsuchihashi T; COMFORT Investigators. Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT study. Clinical and Experimental Hypertension (New York, N.Y.: 1993) 2015;37(3):192-6.
32. Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 2018 Feb;20(2):458-62.
33. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. The New England Journal of Medicine 2018 Mar;378(13):1200-10.
34. Mitnala S, Phipps-Green A, Franklin C, Horne A, Stamp LK, Merriman TR, Dalbeth N. Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology (Oxford, England) 2016 Jul;55(7):1172-6.
35. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. The American Journal of Medicine 1984 Jan;76(1):47-56.
36. Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Annals of the Rheumatic Diseases 2017 Sep;76(9):1522-8.
37. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008 Aug;300(8):924-32.
38. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension (Dallas, Tex.: 1979) 2012 Nov;60(5):1148-56.
39. Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart (British Cardiac Society) 2014 Jul;100(14):1085-92.
40. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clinical Endocrinology (Oxford, England) 2015 Oct;83(4):475-82.
41. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2014 Nov;64(5):1102-7.
42. Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of Medicine 2017 Mar;49(2):142-56.
43. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Archives of Internal Medicine 2010 Aug;170(15):1358-64.
44. MacIsaac RL, Salatzki J, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol and cardiovascular outcomes in adults with hypertension. Hypertension (Dallas, Tex.: 1979) 2016;67(3):535-40.
45. Instructions for medical use of the drug Milurit®. Registration certificate P N012684/01 of 2019 Nov 06. (In Russian).

  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]